Share this article on:

Editorial introductions

Section Editor(s): Kovanen, Petri T.; Newby, Andrew

Current Opinion in Lipidology: October 2012 - Volume 23 - Issue 5 - p v–vi
doi: 10.1097/MOL.0b013e32835956f7
Editorial introductions

Current Opinion in Lipidology was launched in 1990. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of lipidology is divided into six sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.

Back to Top | Article Outline


Petri T. Kovanen

Petri Kovanen studied for his PhD with two of the great lipid pioneers, Esko Nikkilä and Tatu Miettinen at the University of Helsinki, Finland. He subsequently completed postdoctoral training in the laboratory of Nobel Laureates Joseph L. Goldstein and Michael S. Brown, Departments of Molecular Genetics and Internal Medicine at the University of Texas, Health Science Center, Dallas, USA. One of his key achievements here was to define upregulation of hepatic LDL-receptors as the mechanism underlying statin-induced lowering of plasma LDL cholesterol level in vivo. Prof. Kovanen completed his residency in Internal Medicine at the University of Helsinki, and was subsequently appointed Scientific Director of the Wihuri Research Institute, Helsinki, Finland. He is currently Director of the Institute.

His main research interests relate to the pathogenesis of atherosclerosis. A key focus has been exploration of the roles of mast cells as multipotent effector cells in atherothrombosis, both in early atherogenesis, as well as in the generation of vulnerable plaques and associated clinical complications. Prof. Kovanen has published extensively on the pathophysiology of atherosclerosis, specifically proteolytic and lipolytic modification of LDL and HDL.

He has been Editor-in-Chief of Annals of Medicine, and a member of the editorial board of Arteriosclerosis, Thrombosis, and Vascular Biology. He has served as a member of the Council of the Scandinavian Society for Atherosclerosis Research, the European Vascular Biology Organization and is past-President of the Finnish Atherosclerosis Society. He is currently Secretary and Chair of the Scientific Committee of the European Atherosclerosis Society (EAS). He will be Scientific Chair of the 81th EAS Congress, in Lyon, 2013.

Prof. Kovanen has a long association with Current Opinion in Lipidology as Section Editor for Atherosclerosis: cell biology and lipoproteins. With regret, this will be his last year in this capacity.

Back to Top | Article Outline

Andrew Newby

Andrew Newby is British Heart Foundation Professor of Vascular Cell Biology. He graduated in Natural Sciences (Biochemistry) from Cambridge, UK, and studied for a PhD with Professor CN Hales FRS. He then worked on adenylate cyclase with Nobel Laureate Martin Rodbell at the NIH in Bethesda, Maryland, USA. Afterwards, he held a Beit Memorial Fellowship in Cambridge where he elucidated the metabolic pathways responsible for production of the cardioprotective metabolite, adenosine. Subsequently, he was successively Non-clinical Lecturer, Senior Lecturer, Reader and Professor in Cardiff, UK. While continuing to work on adenosine, he contributed to the identification of the endothelium-derived relaxing factor as nitric oxide. He is most known however, for discovering a role for matrix degrading metalloproteinases in vascular smooth muscle cell migration and proliferation in vein grafts, after angioplasty and in atherosclerosis. His elucidation of the inflammatory basis of metalloproteinase production is continuing to shed light on the role of inflammation in plaque rupture and myocardial infarction. He was one of the first vascular biologists to use adenovirus-mediated gene transfer which he now combines with other post-genome technologies. This work has led to more than 150 peer-reviewed research papers and 30 reviews, which have collectively attracted 8000 citations (H>57). It was continuously supported by UK programme grants for the past 20 years. Prof. Newby was also Co-director of the EC-funded European Vascular Genomics Network.

Prof. Newby has served on grants committees of the major UK Research Councils and Charities and also reviewed grants for Belgian, Dutch, French, German and other overseas bodies. His editorial boards include Atherosclerosis, ATVB and Cardiovascular Research.

Prof. Newby has been an EAS member for many years and recently served on the Programme Committee for the Helsinki and Gothenburg congresses. He has more than 20 years involvement with the European Society of Cardiology, being a founder member and later Chair of the working group Pathogenesis of Atherosclerosis, a member of the Congress Programme Committee and Chairman of the Council on Basic Cardiovascular Science. He now dedicates himself to running the biennial ESC Summer Schools in Cardiovascular Biology. Perhaps most significantly he re-launched, and was President of, the European Vascular Biology Organisation from 2006 to 2010.

Copyright © 2012 Wolters Kluwer Health, Inc. All rights reserved.